Skip to main content

Table 2 CMR Baseline Characteristics

From: Comparison of myocardial fibrosis quantification methods by cardiovascular magnetic resonance imaging for risk stratification of patients with suspected myocarditis

 

All patients

(n = 670)

LVEF (%)

50 ± 15

LVEDVi (ml/m2)

98 ± 33

LVESVi (ml/m2)

53 ± 34

LV mass index (g/m2)

61 ± 17

RVEF (%)

49 ± 11

RVEDVi (ml/m2)

80 ± 21

RVESVi (ml/m2)

42 ± 17

Pericardial effusion

169 (25%)

T2- weighted imaging (SIR ≥2)

124 (27%)

LGE presence

292 (44%)

LGE-VPS

1.7 ± 3.4

LGE-VTS

4.2 ± 8.9

LGE mass (g)

 - 2-SD

5.5 ± 10.6

 - 3-SD

3.7 ± 7.7

 - 4-SD

2.6 ± 5.8

 - 5-SD

1.7 ± 4.1

 - 6-SD

1.2 ± 3.2

 - 7-SD

0.8 ± 2.4

 - FWHM

2.7 ± 5.3

LGE mass (%)

 - 2-SD

4.7 ± 8.8

 - 3-SD

3.1 ± 6.5

 - 4-SD

2.2 ± 4.9

 - 5-SD

1.5 ± 3.5

 - 6-SD

1.0 ± 2.7

 - 7-SD

0.7 ± 2.1

 - FWHM

2.2 ± 4.5

  1. CMR cardiovascular magnetic resonance imaging, LVEF left ventricular ejection fraction, LVEDVi left ventricular end diastolic volume indexed, LVESVi left ventricular end systolic volume index, RVEF right ventricular ejection fraction, RVEDVi right ventricular end-diastolic volume index, RVESVi right ventricular end-systolic volume index, LGE late gadolinium enhancement,. SIR signal intensity ratio (ratio of signal in myocardium divided by signal in skeletal muscle), VPS visual presence score, VTS visual transmurality score, FWHM full width half maximum;
  2. T2 weighted imaging is available in 465 patients